GE Healthcare to Acquire Radiopharma Firm Sofie Biosciences for $945M
The acquisition adds 15 U.S. manufacturing sites and 21 cyclotrons, expanding GE HealthCare’s radiopharmaceutical supply network and access to F18 PET products.
- On Monday, GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences from private equity firm Trilantic North America for $945 million in cash, with closing expected in the first half of 2027.
- The acquisition bolsters GE HealthCare's Pharmaceutical Diagnostics segment by adding 15 Contract Manufacturing Organization sites and 21 cyclotrons, expanding the company's infrastructure to manufacture and distribute PET imaging drugs.
- GE HealthCare gains U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, while its imaging agents support 140 million procedures annually across care pathways.
- Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare, stated SOFIE will continue operating as an independent manufacturing partner, and the company will "leverage our scale and expertise" to grow the business.
- This deal follows Curium's $8 billion acquisition of Lantheus in August, reflecting rising industry consolidation as firms capitalize on approximately 20 PET radiotracers and 30 radiotherapeutics currently under development.
17 Articles
17 Articles
GE HealthCare Technologies announced on Monday (5) the acquisition, entirely in cash, of the Sofie Biosciences radio imaging product manufacturer, in a movement to expand its presence in the rapidly growing radiopharmaceutical market. GE HealthCare will pay US$ 945 million for Sofie's current controller, the private equity company Trilantic North America. Exclusive material for subscribers. To have full access, access the link of the material an…
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture and distribute PET imaging drugs.
Financial Post
India ShortsGE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
Broadens GE HealthCare’s footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to […
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
